+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast -2032

  • PDF Icon

    Report

  • 276 Pages
  • January 2022
  • Region: Global
  • DelveInsight
  • ID: 4463954
UP TO OFF until Dec 31st 2024
This "Multiple Sclerosis- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Multiple Sclerosis market report provides current treatment practices, emerging drugs, Multiple Sclerosis market share of the individual therapies, current and forecasted Multiple Sclerosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Multiple Sclerosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Multiple Sclerosis Disease Understanding and Treatment Algorithm


The Multiple Sclerosis market report gives a thorough understanding of the Multiple Sclerosis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Multiple Sclerosis.

Treatment


It covers the details of conventional and current medical therapies available in the Multiple Sclerosis market for the treatment of the condition. It also provides Multiple Sclerosis treatment algorithms and guidelines in the United States, Europe, and Japan.

Multiple Sclerosis Epidemiology


The Multiple Sclerosis epidemiology division provide insights about historical and current Multiple Sclerosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Multiple Sclerosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Multiple Sclerosis Epidemiology


The epidemiology segment also provides the Multiple Sclerosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Multiple Sclerosis Drug Chapters


Drug chapter segment of the Multiple Sclerosis report encloses the detailed analysis of Multiple Sclerosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Sclerosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Multiple Sclerosis treatment.

Multiple Sclerosis Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Multiple Sclerosis treatment.

Multiple Sclerosis Market Outlook


The Multiple Sclerosis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Multiple Sclerosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Multiple Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Multiple Sclerosis market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Multiple Sclerosis market in 7MM.

The United States Market Outlook


This section provides the total Multiple Sclerosis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Multiple Sclerosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Multiple Sclerosis market size and market size by therapies in Japan is also mentioned.

Multiple Sclerosis Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Multiple Sclerosis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Sclerosis Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Multiple Sclerosis key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Multiple Sclerosis emerging therapies.

Reimbursement Scenario in Multiple Sclerosis


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Multiple Sclerosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Multiple Sclerosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Multiple Sclerosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Multiple Sclerosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Multiple Sclerosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Sclerosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Multiple Sclerosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Sclerosis market

Report Highlights

  • In the coming years, Multiple Sclerosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Multiple Sclerosis. Launch of emerging therapies will significantly impact the Multiple Sclerosis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Multiple Sclerosis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Multiple Sclerosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Multiple Sclerosis Pipeline Analysis
  • Multiple Sclerosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Multiple Sclerosis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Multiple Sclerosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple Sclerosis Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Multiple Sclerosis market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Multiple Sclerosis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Multiple Sclerosis market size during the forecast period (2019-2032)?
  • At what CAGR, the Multiple Sclerosis market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Multiple Sclerosis market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Multiple Sclerosis market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Multiple Sclerosis?
  • What is the historical Multiple Sclerosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Multiple Sclerosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Multiple Sclerosis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Multiple Sclerosis during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Multiple Sclerosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Multiple Sclerosis in the USA, Europe, and Japan?
  • What are the Multiple Sclerosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Multiple Sclerosis?
  • How many therapies are developed by each company for Multiple Sclerosis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Multiple Sclerosis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Multiple Sclerosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Multiple Sclerosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Multiple Sclerosis?
  • What are the global historical and forecasted market of Multiple Sclerosis?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Multiple Sclerosis market
  • To understand the future market competition in the Multiple Sclerosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis market
  • To understand the future market competition in the Multiple Sclerosis market

Table of Contents

1 Key Insights2 Report Introduction
3 Multiple Sclerosis Market Overview at a Glance
3.1 Market Share (%) Distribution of Multiple Sclerosis in 2019
3.2 Market Share (%) Distribution of Multiple Sclerosis in 2032
4 Executive Summary of Multiple Sclerosis
5 Disease Background and Overview
5.1 Introduction
5.2 Signs and Symptoms
5.3 Classification Systems
5.4 Etiology
5.4.1 Genetic Susceptibility
5.4.2 Infectious Factors and Viruses
5.4.3 Environmental Factors
5.5 Risk Factors
5.6 Pathogenesis
5.7 Pathophysiology
5.7.1 Acute Active Plaques
5.7.2 Chronic Plaques
5.7.3 Remyelinated Plaques
5.7.4 Cortical Demyelinated Lesions in Early Multiple Sclerosis
5.8 Clinical Manifestations
5.9 Diagnosis
5.9.1 Diagnostic Criteria
6 Treatment of MS7 Management of MS
8 Guidelines
8.1 ECTRIMS/EAN guidelines on the pharmacological treatment of people with MS
8.2 American Academy of Neurology
9 Epidemiology and Patient Population
9.1 Key Findings
9.2 7MM Total Prevalent Patient Population of Multiple Sclerosis
9.3 Assumptions and Rationales
9.4 The United States
9.4.1 Total Prevalent Cases of Multiple Sclerosis in the United States
9.4.2 Prevalence of Multiple Sclerosis based on Gender in the United States
9.4.3 Phenotype specific prevalent cases of Multiple Sclerosis in the United States
9.4.4 Prevalence of Multiple Sclerosis based on Age in the United States
9.4.5 EDSS of the United States
9.5 EU-5
9.5.1 Total Prevalent Cases of Multiple Sclerosis in EU-5
9.5.2 Prevalence of Multiple Sclerosis based on Gender in EU-5
9.5.3 Phenotype specific prevalent cases of Multiple Sclerosis in EU-5
9.5.4 Prevalence of Multiple Sclerosis based on Age in EU-5
9.5.5 EDSS of EU-5
9.6 Japan
9.6.1 Total Prevalent Cases of Multiple Sclerosis in Japan
9.6.2 Prevalence of Multiple Sclerosis based on Gender in Japan
9.6.3 Phenotype specific prevalent cases of Multiple Sclerosis in Japan
9.6.4 Prevalence of Multiple Sclerosis based on Age in Japan
9.6.5 EDSS of Japan
10 Patient Journey 111 Patient Journey 2
12 Emerging Therapies
12.1 NeuroVax: Immune Response BioPharma, Inc.
12.1.1 Product Description
12.1.2 Other Developmental Activities
12.1.3 Clinical Development
12.1.4 Clinical Trials Information
12.1.5 Product Profile
12.2 CNM-Au8: Clene Nanomedicine
12.2.1 Product Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.4 Clinical Trials Information
12.2.5 Safety and efficacy
12.2.6 Product Profile
12.3 Tolebrutinib (SAR442168): Sanofi
12.3.1 Product Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.4 Clinical Trials Information
12.3.5 Safety and efficacy
12.3.6 Product Profile
12.4 Evobrutinib/M2951: Merck Healthcare KGaA
12.4.1 Product Description
12.4.2 Clinical Development
12.4.3 Clinical Trials Information
12.4.4 Safety and efficacy
12.4.5 Product Profile
12.5 Ublituximab: TG Therapeutics, Inc.
12.5.1 Product Description
12.5.2 Other Developmental Activities
12.5.3 Clinical Development
12.5.4 Clinical Trials Information
12.5.5 Safety and efficacy
12.5.6 Product Profile
13 Other Emerging Drugs
13.1 Apitox: Apimeds Inc.
13.2 Nabiximols Oromucosal Spray as Add-on Therapy: GW Pharmaceuticals Ltd.
14 Marketed Therapies
14.1 Betaseron® (Interferon beta-1b): Bayer HealthCare Pharmaceuticals/Novartis
14.1.1 Product Description
14.1.2 Mechanism of action
14.1.3 Regulatory Milestones
14.1.4 Other Developmental Activities
14.1.5 Advantages and Disadvantages
14.1.6 Safety and Efficacy
14.1.7 Product Profile
14.2 Avonex (Interferon beta-1a): Biogen
14.2.1 Product Description
14.2.2 Mechanism of action
14.2.3 Regulatory Milestones
14.2.4 Other Developmental Activities
14.2.5 Advantages and Disadvantages
14.2.6 Product Profile
14.3 Gilenya (Fingolimod): Novartis
14.3.1 Product Description
14.3.2 Mechanism of action
14.3.3 Regulatory Milestones
14.3.4 Other Developmental Activities
14.3.5 Advantages and Disadvantages
14.3.6 Safety and Efficacy
14.3.7 Product Profile
14.4 Vumerity (Diroximel fumarate): Alkermes/Biogen
14.4.1 Product Description
14.4.2 Mechanism of action
14.4.3 Regulatory Milestones
14.4.4 Other Developmental Activities
14.4.5 Advantages and Disadvantages
14.4.6 Safety and Efficacy
14.4.7 Product Profile
14.5 Ocrevus (Ocrelizumab): Biogen/Genentech
14.5.1 Product Description
14.5.2 Mechanism of action
14.5.3 Regulatory Milestones
14.5.4 Other Developmental Activities
14.5.5 Safety and Efficacy
14.5.6 Product Profile
15 Multiple Sclerosis: 7 Major Market Analysis
15.1 Key Findings
15.2 Market Size of Multiple Sclerosis in 7MM
15.3 Market Size of Multiple Sclerosis by Therapies
16 Market Outlook
16.1 United States Market Size
16.1.1 Total Market Size of Multiple Sclerosis in the United States
16.1.2 Market Size of Multiple Sclerosis by Therapies in United States
16.2 EU-5 Market Size
16.2.1 Total Market size of Multiple Sclerosis in EU-5
16.2.2 Market Size of Multiple Sclerosis Therapies in EU-5
16.3 Japan
16.3.1 Total Market size of Multiple Sclerosis in Japan
16.3.2 Market Size of Multiple Sclerosis by Therapies in Japan
17 Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US
17.1 Total Annual Utilization and Reimbursement of All Study Drugs
17.2 Total Annual Reimbursement of All Study Drugs
17.3 Annual Cost per Prescription of Each Study Drug
17.4 Market Share
18 KOL Views19 Unmet Needs20 Market Drivers21 Market Barriers22 SWOT Analysis
23 Appendix
23.1 Bibliography
23.2 Report Methodology
24 Capabilities25 Disclaimer26 About the Publisher
List of Tables
Table 1: Summary of Multiple Sclerosis, Market, Epidemiology, and Key Events (2019-2032)
Table 2: Differential Diagnosis of Multiple Sclerosis
Table 3: Symptomatic treatment of Multiple Sclerosis
Table 4: Total Prevalent Patient Population of Multiple Sclerosis in 7MM in 000’s (2019-2032)
Table 5: Total Prevalent Cases of Multiple Sclerosis in the United States in 000's (2019-2032)
Table 6: Prevalence of Multiple Sclerosis based on Gender in the United States in 000's (2019-2032)
Table 7: Phenotype specific Prevalent cases of Multiple Sclerosis in the United States in 000's (2019-2032)
Table 8: Prevalence of Multiple Sclerosis based on Age in the United States in 000's (2019-2032)
Table 9: EDSS of the United States in 000’s (2019-2032)
Table 10: Total Prevalent Cases of Multiple Sclerosis in EU-5 in 000's (2019-2032)
Table 11: Prevalence of Multiple Sclerosis based on Gender in EU-5 in 000's (2019-2032)
Table 12: Phenotype specific Prevalent cases of Multiple Sclerosis in EU-5 in 000's (2019-2032)
Table 13: Prevalence of Multiple Sclerosis based on Age in EU-5 in 000's (2019-2032)
Table 14: EDSS of EU-5 in 000's (2019-2032)
Table 15: Total Prevalent Cases of Multiple Sclerosis in Japan in 000's (2019-2032)
Table 16: Prevalence of Multiple Sclerosis based on Gender in Japan in 000's (2019-2032)
Table 17: Phenotype specific Prevalent cases of Multiple Sclerosis in Japan in 000's (2019-2032)
Table 18: Prevalence of Multiple Sclerosis based on Age in Japan in 000’s (2019-2032)
Table 19: EDSS of Japan in 000’s (2019-2032)
Table 20: NeuroVax, Clinical Trial Description, 2021
Table 21: CNM-Au8, Clinical Trial Description, 2021
Table 22: Tolebrutinib , Clinical Trial Description, 2021
Table 23: Evobrutinib, Clinical Trial Description, 2021
Table 24: Ublituximab, Clinical Trial Description, 2021
Table 25: ALKS 8700, Clinical Trial Description, 2021
Table 26: Arbaclofen, Clinical Trial Description, 2021
Table 27: Masitinib, Clinical Trial Description, 2021
Table 28: Fenebrutinib, Clinical Trial Description, 2021
Table 29: 7 Major Market Size of Multiple Sclerosis in USD Million (2019-2032)
Table 30: 7 Major Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Table 31: United States Market Size of Multiple Sclerosis in USD Million (2019-2032)
Table 32: United States Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Table 33: EU-5 Market Size of Multiple Sclerosis in USD Million (2019-2032)
Table 34: EU-5 Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Table 35: Japan Market Size of Multiple Sclerosis in USD Million (2019-2032)
Table 36: Japan Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
List of Figures
Figure 1: Types of Multiple Sclerosis
Figure 2: The Most Common Risk Factors for Multiple Sclerosis (MS)
Figure 3: Mechanisms of action for IFNß in multiple sclerosis. Interferon beta exerts its biological effects by binding to specific receptors on the surface of human cells. This binding initiates a complex cascade of intracellular events that leads to the expression of numerous interferon-induced gene products and markers
Figure 4: Total Prevalent Population of Multiple Sclerosis in 7MM in 000’s (2019-2032)
Figure 5: Total Prevalent Cases of Multiple Sclerosis in the United States in 000's (2019-2032)
Figure 6: Prevalence of Multiple Sclerosis based on Gender in the United States in 000's (2019-2032)
Figure 7: Phenotype specific Prevalent cases of Multiple Sclerosis in the United States in 000's (2019-2032)
Figure 8: Prevalence of Multiple Sclerosis based on Age in the United States in 000's (2019-2032)
Figure 9: EDSS of the United States in 000’s (2019-2032)
Figure 10: Total Prevalent Cases of Multiple Sclerosis in EU-5 in 000’s (2019-2032)
Figure 11: Prevalence of Multiple Sclerosis based on Gender in EU-5 in 000’s (2019-2032)
Figure 12: Phenotype specific Prevalent cases of Multiple Sclerosis in EU-5 in 000’s (2019-2032)
Figure 13: Prevalence of Multiple Sclerosis based on Age in EU-5 in 000's (2019-2032)
Figure 14: EDSS of EU-5 in 000’s (2019-2032)
Figure 15: Total Prevalent Cases of Multiple Sclerosis in Japan in 000's (2019-2032)
Figure 16: Prevalence of Multiple Sclerosis based on Gender in Japan in 000's (2019-2032)
Figure 17: Phenotype specific Prevalent cases of Multiple Sclerosis in Japan in 000's (2019-2032)
Figure 18: Prevalence of Multiple Sclerosis based on Age in Japan in 000's (2019-2032)
Figure 19: EDSS of Japan in 000’s (2019-2032)
Figure 20: 7 Major Market Size of Multiple Sclerosis in USD Million (2019-2032)
Figure 21: 7 Major Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Figure 22: Total Market Size of Multiple Sclerosis in the United States, USD Million (2019-2032)
Figure 23: The United States Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Figure 24: Total Market Size of Multiple Sclerosis in EU-5, USD Million (2019-2032)
Figure 25: EU-5 Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Figure 26: Market Size of Multiple Sclerosis in Japan, USD Million (2019-2032)
Figure 27: The Japan Market Size of Multiple Sclerosis by Therapies in USD Million (2019-2032)
Figure 28a: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 29b: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 30c: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 31a: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 32b: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 33c: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008-2019, by Route of Administration
Figure 34a: Annual Market Share of Each Drug Category, Represented as Percentage, 2008-2019
Figure 35b: Annual Market Share of Each Drug Category, Represented as Percentage, 2008-2019

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Immune Response BioPharma, Inc.
  • Clene Nanomedicine
  • Sanofi
  • Merck Healthcare KGaA
  • TG Therapeutics, Inc.
  • Apimeds Inc.
  • Bayer HealthCare
  • Novartis
  • Biogen
  • Alkermes
  • Genentech